Melbourne, Australia; March 14 and New York, USA; March 13, 2024:
Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has received firm commitments to complete its pro-rata accelerated nonrenounceable entitlement offer that was launched on 4 December, 2023 (Entitlement Offer). Together the entitlement offer and institutional placement raised gross proceeds of A$97 million, including A$36.7 million committed today on the same terms as the Entitlement Offer, primarily from Mesoblast’s existing major shareholders.
Dr. Eric Rose, the Company’s Chief Medical Officer and a director of Mesoblast, subscribed for additional shares of A$1.5 million, subject to shareholder approval. Dr. Rose is a world-renowned heart surgeon who performed the world’s first successful heart transplant in children and was for many years Chairman of Columbia University’s Department of Surgery. Dr. Rose was the Principal Investigator of the pivotal trial resulting in FDA approval of the first implantable left ventricular assist device (LVAD) for long term support of patients with heart failure, spawning an entire new industry.
240314-ASX-MSB-MESOBLAST-SUCCESSFULLY-COMPLETES-PLACEMENT-AND-ACCELERATED-ENTITLEMENT-OFFER
